White Plains, New York, United States In 1944 was created Leukemia & Lymphoma Society, which is appeared as Corporate Investor. The venture was found in North America in United States. The leading representative office of defined Corporate Investor is situated in the White Plains.
The usual cause for the fund is to invest in rounds with 1 partaker. Despite the Leukemia & Lymphoma Society, startups are often financed by Sutter Hill Ventures, National Institutes of Health, Lightspeed Venture Partners. In the next rounds fund is usually obtained by GlaxoSmithKline, Celgene.
Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Health Care, Pharmaceutical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has specific favorite in a number of founders of portfolio startups. Among the various public portfolio startups of the fund, we may underline OncoPep, Epizyme
The increased amount of exits for fund were in 2013. The top activity for fund was in 2019. The common things for fund are deals in the range of 5 - 10 millions dollars. The fund is generally included in less than 2 deals every year.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Derui Qiyuan Venture Capital | China, Guangdong, Shenzhen |
| Encubate Holdings | Atlanta, Georgia, United States |
| Forage Capital Partners | Alberta, Calgary, Canada |
| Junpu | Japan, Tokyo |
| Midas Ventures | Brazil, São Paulo, Sao Paulo |
| Partners Bank of California | - |
| PRIME Impact Fund | Cambridge, Massachusetts, United States |
| Sprout BioVentures | - |
| venVelo | Florida, United States, Winter Park |
| Zhuji Hongyi Cultural Industry Investment | China, Zhejiang, Zhuji |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
ImCheck Therapeutics | $113M | 13 Jun 2022 | Marseille, Provence-Alpes-Côte d'Azur, France | ||
Immunitas Therapeutics | $58M | 18 Aug 2021 | Cambridge, Massachusetts, United States | ||
Dimericon Therapeutics | 01 May 2021 | Zürich, Zurich, Switzerland | |||
| $73M | 30 Mar 2021 | Palo Alto, California, United States | |||
Caribou Biosciences | $115M | 03 Mar 2021 | Berkeley, California, United States | ||
| $6M | 28 Aug 2014 | Massachusetts, United States | |||
Constellation Pharmaceuticals | 01 Sep 2012 | Cambridge, Massachusetts, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
ImCheck Therapeutics | $113M | 13 Jun 2022 | Marseille, Provence-Alpes-Côte d'Azur, France | ||
Immunitas Therapeutics | $58M | 18 Aug 2021 | Cambridge, Massachusetts, United States | ||
Dimericon Therapeutics | 01 May 2021 | Zürich, Zurich, Switzerland | |||
| $73M | 30 Mar 2021 | Palo Alto, California, United States | |||
Caribou Biosciences | $115M | 03 Mar 2021 | Berkeley, California, United States | ||
| $6M | 28 Aug 2014 | Massachusetts, United States | |||
Constellation Pharmaceuticals | 01 Sep 2012 | Cambridge, Massachusetts, United States |
